EasyNAT Human Parvovirus B19 Assay
Ongoing Challanges
The demand for Human Parvovirus B19 (HPV B19) testing arises from the need to diagnose various conditions caused by the virus, such as erythema infectiosum in children, pregnancy complications, aplastic crises in patients with blood disorders, and chronic anemia in immunocompromised individuals.
Immunocompromised patients (e.g., those with HIV/AIDS or organ transplant recipients) may not produce a sufficient antibody response, making serological tests less reliable.
Product Overview
The EasyNAT® Human Parvovirus B19 Assay is an automated, in vitro nucleic acid amplification test for the qualitative detection of Human Parvovirus B19 DNA in human serum or plasma specimens.
Results available within 39 minutes
Designed to provide an accurate LOD: 1000 copies/mL
Moderately complex testing with less than 1 minute of hands-on time
Provides swift results for patients with suspected Human Parvovirus B19 infection
User-friendly direct diagnostic test
Clinical Value
Improves detection of Human Parvovirus B19 during the window period or in individuals with immune deficiency.
Avoids cross-reactivity with other pathogens.
Designed for use in clinical laboratories as well as near-patient settings.
Can be performed by non-laboratory professionals, such as labor and delivery nurses, operating 24/7.
